Kailera priced its initial public offering at $625 million on Thursday, marking the largest U.S. biotech debut in twenty-eight months and the first nine-figure obesity-linked raise since the GLP-1 category entered institutional discourse. The company, which develops neuropsychiatric therapies with metabolic crossover potential, priced above the indicated range. CEO remarks suggest the syndicate knew demand two weeks before launch.

The offering moved 41.7 million shares at $15 per share, above the $12-$14 range filed in late March. Underwriters exercised a partial greenshoe within twelve hours. Kailera's lead program, a dual-mechanism oral candidate targeting binge-eating disorder and metabolic syndrome, remains in Phase II with topline data expected fourth quarter. The company holds $780 million in pro forma cash, sufficient for three pivotal trials without dilution through 2027.

This matters because the biotech IPO window has been functionally closed since November 2021, when the Nasdaq Biotech Index peaked at 4,950 and began a two-year contraction. Kailera's successful pricing suggests institutional appetite for obesity-adjacent stories has separated from broader biotech sentiment. The company is not a GLP-1 developer—its mechanism involves serotonin modulation and dopamine reuptake—but it benefits from the halo. Allocators who sat out Eli Lilly at $310 and Novo Nordisk at $105 are hunting earlier-stage metabolic exposure. Kailera offered that entry point with a credible Phase II dataset and a management team that previously took two CNS assets through approval.

The pricing also confirms a two-tier IPO market. Companies with obesity, inflammation, or oncology narratives and at least Phase II data can access public capital. Everything else remains private or sells to strategics at compressed multiples. Kailera's success will likely pull forward three to five similar filings over the next ninety days, particularly from firms with GLP-1 combination strategies or oral formulations. The syndicate was Goldman Sachs, JPMorgan, and Jefferies. Goldman has nine biotech IPOs in registration; six have obesity or metabolic components.

Operators should track Kailera's 90-day lockup expiration in mid-July and monitor whether the stock holds above the $15 issue price through the June ASCO conference, where the company presents preclinical data on a second candidate. If the stock trades below $13.50 by early May, it signals the IPO was mistimed or overpriced, and the window tightens again. If it holds or rallies, expect the syndicate to accelerate five filings currently in quiet period. The Nasdaq Biotech Index sits at 4,102, still 17% below its 2021 peak, meaning sector rotation has not yet occurred—this is selective thematic buying.

Kailera begins trading Friday under ticker KALR. The company's burn rate is $18 million per quarter, and it has no debt.